257 related articles for article (PubMed ID: 25891704)
21. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
[TBL] [Abstract][Full Text] [Related]
22. Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study.
Deltombe C; Gillaizeau F; Anglicheau D; Morelon E; Trébern-Launay K; Le Borgne F; Rimbert M; Guérif P; Malard-Castagnet S; Foucher Y; Giral M
Transpl Int; 2017 Nov; 30(11):1150-1160. PubMed ID: 28686316
[TBL] [Abstract][Full Text] [Related]
23. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients.
Reinsmoen NL; Lai CH; Heidecke H; Haas M; Cao K; Ong G; Naim M; Wang Q; Mirocha J; Kahwaji J; Vo AA; Jordan SC; Dragun D
Transplantation; 2010 Dec; 90(12):1473-7. PubMed ID: 21030904
[TBL] [Abstract][Full Text] [Related]
24. Preformed Angiotensin II Type-1 Receptor Antibodies Are Associated With Rejection After Kidney Transplantation: A Single-Center, Cohort Study.
Kim D; Gimferrer I; Warner P; Nelson K; Sibulesky L; Bakthavatsalam R; Leca N
Transplant Proc; 2018 Dec; 50(10):3467-3472. PubMed ID: 30577222
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.
Eskandary F; Bond G; Kozakowski N; Regele H; Marinova L; Wahrmann M; Kikić Ž; Haslacher H; Rasoul-Rockenschaub S; Kaltenecker CC; König F; Hidalgo LG; Oberbauer R; Halloran PF; Böhmig GA
Transplantation; 2017 Mar; 101(3):631-641. PubMed ID: 27120452
[TBL] [Abstract][Full Text] [Related]
26. Circulating angiotensin type II receptor: Possible marker for antibody mediated rejection after renal transplantation?
Kimball PM; Gupta G; McDougan F
Hum Immunol; 2017 Oct; 78(10):629-633. PubMed ID: 28614703
[TBL] [Abstract][Full Text] [Related]
27. Clinical conundrums in pediatric kidney transplantation: What we know about the role of angiotensin II type I receptor antibodies in pediatric kidney transplantation and the path forward.
Pearl MH
Pediatr Transplant; 2024 May; 28(3):e14762. PubMed ID: 38650537
[TBL] [Abstract][Full Text] [Related]
28. Levels of angiotensin II type-1 receptor antibodies and endothelin-1 type-A receptor antibodies correlate with antibody-mediated rejection and poor graft function in kidney-transplantation patients.
Liu C; Kang ZY; Yin Z; Xiao Y; Liu W; Zhao Y; Li DH
Transpl Immunol; 2022 Oct; 74():101674. PubMed ID: 35901953
[TBL] [Abstract][Full Text] [Related]
29. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
[TBL] [Abstract][Full Text] [Related]
30. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss.
Fidler S; Swaminathan R; Lim W; Ferrari P; Witt C; Christiansen FT; D'Orsogna LJ; Irish AB
Transpl Immunol; 2013 Dec; 29(1-4):22-7. PubMed ID: 24090807
[TBL] [Abstract][Full Text] [Related]
31. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.
Yamamoto T; Watarai Y; Takeda A; Tsujita M; Hiramitsu T; Goto N; Narumi S; Katayama A; Morozumi K; Uchida K; Kobayashi T
Transplantation; 2016 Oct; 100(10):2194-202. PubMed ID: 26636737
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
33. The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients.
Urban M; Slavcev A; Gazdic T; Ivak P; Besik J; Netuka I
Interact Cardiovasc Thorac Surg; 2016 Mar; 22(3):292-7. PubMed ID: 26675563
[TBL] [Abstract][Full Text] [Related]
34. Plasma C4d+ Endothelial Microvesicles Increase in Acute Antibody-Mediated Rejection.
Tower CM; Reyes M; Nelson K; Leca N; Kieran N; Muczynski K; Jefferson JA; Blosser C; Kukla A; Maurer D; Chandler W; Najafian B
Transplantation; 2017 Sep; 101(9):2235-2243. PubMed ID: 27846156
[TBL] [Abstract][Full Text] [Related]
35. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
37. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
[TBL] [Abstract][Full Text] [Related]
38. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies.
Fuss A; Hope CM; Deayton S; Bennett GD; Holdsworth R; Carroll RP; Coates PT
Nephrology (Carlton); 2015 Jul; 20(7):467-73. PubMed ID: 25726938
[TBL] [Abstract][Full Text] [Related]
39. Clinical and pathological analyses of transplant glomerulopathy cases.
Shimizu T; Ishida H; Toki D; Nozaki T; Omoto K; Tanabe K; Honda K; Koike J
Nephrology (Carlton); 2014 Jun; 19 Suppl 3():21-6. PubMed ID: 24842817
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
